Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative

医学 楔形切除术 腺癌 肺癌 外科 内科学 癌症 切除术
作者
Di Li,Chaoqiang Deng,Shengping Wang,Yuan Li,Yang Zhang,Haiquan Chen
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [American Association for Thoracic Surgery]
卷期号:164 (6): 1614-1622.e1 被引量:9
标识
DOI:10.1016/j.jtcvs.2022.06.017
摘要

Objective This study aimed to reveal the long-term outcomes of patients with lung cancer with adenocarcinoma in situ or minimally invasive adenocarcinoma after resection, in the context of the different surgical resection types. Methods Patients with lung adenocarcinoma who underwent resection between December 2007 and December 2012 were reviewed. Patients with pathological adenocarcinoma in situ or minimally invasive adenocarcinoma were enrolled. Postoperative survival and risk of developing second primary lung cancer were analyzed. Results After reevaluating the histological findings of 1696 patients with lung adenocarcinoma, we enrolled 53 with adenocarcinoma in situ and 72 with minimally invasive adenocarcinoma for analyses. Of all 125 patients with adenocarcinoma in situ/minimally invasive adenocarcinoma, 86 (68.8%) were female, 114 (91.2%) were nonsmokers, and most of them (78, 62.4%) underwent wedge resection. The median follow-up period after surgery was 111 months. The 10-year recurrence-free survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were all 100%, and the 10-year overall survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were 98.1% and 97.2%, respectively. There was no difference in 10-year recurrence-free survival between patients who underwent lobectomy and wedge resection. EGFR mutations were detected in 63.1% (41/65) of patients who underwent mutational analysis. The risks of developing second primary lung cancer for adenocarcinoma in situ and minimally invasive adenocarcinoma 10 years after resection were 8.4% and 4.3% (P = .298), respectively, and were not correlated with EGFR mutation status (P = .525). Conclusions Pathological adenocarcinoma in situ and minimally invasive adenocarcinoma have no recurrence during 10-year follow-up after resection, regardless of surgical procedure types. Surgery is curative for these patients, and wedge resection is the preferred surgical procedure for nodules in the proper location.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我刚上小学完成签到,获得积分10
2秒前
weww完成签到 ,获得积分10
4秒前
yiding完成签到 ,获得积分10
4秒前
冻冻妖完成签到,获得积分10
4秒前
Raine发布了新的文献求助10
4秒前
简单而复杂完成签到,获得积分10
5秒前
Ploaris发布了新的文献求助30
5秒前
1+1完成签到,获得积分10
5秒前
李健的小迷弟应助antirun采纳,获得30
15秒前
青山完成签到 ,获得积分10
18秒前
迅速的以山关注了科研通微信公众号
19秒前
无花果应助你好CDY采纳,获得10
21秒前
22秒前
jzh601完成签到,获得积分10
22秒前
23秒前
神奇海螺完成签到,获得积分10
25秒前
26秒前
Ploaris完成签到 ,获得积分10
26秒前
学不完的玛卡巴卡卡完成签到 ,获得积分10
27秒前
李爱国应助year采纳,获得10
27秒前
芒岁发布了新的文献求助10
28秒前
定格完成签到 ,获得积分10
29秒前
wbgwudi完成签到,获得积分10
29秒前
antirun发布了新的文献求助30
29秒前
菜菜菜发布了新的文献求助10
32秒前
32秒前
FashionBoy应助jzh601采纳,获得10
33秒前
充电宝应助lin采纳,获得10
34秒前
34秒前
英俊的铭应助panting采纳,获得10
36秒前
antirun完成签到,获得积分10
36秒前
Zmj20011220完成签到,获得积分10
36秒前
英俊的铭应助maohuibai采纳,获得10
37秒前
37秒前
芒岁完成签到,获得积分10
38秒前
Zmj20011220发布了新的文献求助30
41秒前
43秒前
小蘑菇应助自然的初丹采纳,获得10
44秒前
46秒前
你好CDY发布了新的文献求助10
49秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
薩提亞模式團體方案對青年情侶輔導效果之研究 400
3X3 Basketball: Everything You Need to Know 310
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2388452
求助须知:如何正确求助?哪些是违规求助? 2094766
关于积分的说明 5274075
捐赠科研通 1821629
什么是DOI,文献DOI怎么找? 908673
版权声明 559437
科研通“疑难数据库(出版商)”最低求助积分说明 485505